Abstract
Chronic lymphocytic leukemia (CLL) is the most common indolent leukemia in the United States (Bnaya et al., 2021). Metabolic complications (e.g., hyperkalemia, hyperuricemia, hypocalcemia) are particularly common in patients with unstable CLL and are caused by rapid cellular destruction (Higdon et al., 2018). Empirical reports emphasize that these derangements can lead to acute urate nephropathy, sudden cardiac arrest, and death, particularly with progressive disease or in those receiving active CLL-directed therapy (Higdon et al., 2018; Koehler et al., 2020).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
